Silvia Coma
Senior Director - Translational & Preclinical Research Verastem. inc
Dr. Coma has over 20 years of experience in oncology research and 10 years of pharmaceutical/biotech industry experience, including small molecules and antibody drug discovery, and immuno-oncology. She joined Verastem in 2019 and has been leading the preclinical and translational research targeting RAS-dependent cancers with the company’s clinical stage RAF/MEK, FAK and KRAS G12D inhibitors. Dr. Coma did postdoctoral work at Boston Children’s Hospital in the laboratory of Dr. Michael Klagsbrun and holds a Ph.D. in cancer Biology from the University of Barcelona.
Seminars
Tuesday 8th September 2026
Panel Discussion: How Do We Build Combination Strategies That Work Across KRAS Alleles, Co Mutations, & Tumor Types?
1:00 pm
- How do KRAS alleles, co‑mutations, and tumor lineage reshape dependency and escape, and what does that mean for choosing the right combination backbone?
- Which combinations have true cross‑context potential, and which are only effective in specific molecular or tumor‑type settings?
- How should we prioritise combinations that balance biological rationale, toxicity constraints, and real‑world feasibility across heterogeneous patient populations?
